XTNT
AMEXXtant Medical Holdings Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$0.34-0.11 (-24.80%)
2026-05-202026-08-24
News · 26 weeks35+100%
2026-03-012026-08-23
Mix1790d
- Insider8(47%)
- SEC Filings5(29%)
- Other2(12%)
- Earnings2(12%)
Latest news
25 items- INSIDERDirector Lipschultz Tyler was granted 215,517 shares, increasing direct ownership by 136% to 373,745 units (SEC Form 4)4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
- INSIDERDirector Bakewell John K was granted 215,517 shares, increasing direct ownership by 24% to 1,129,633 units (SEC Form 4)4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
- INSIDERDirector Beeson Jonn R. was granted 215,517 shares, increasing direct ownership by 42% to 733,136 units (SEC Form 4)4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
- INSIDERDirector Jain Abhinav was granted 215,517 shares, increasing direct ownership by 136% to 373,745 units (SEC Form 4)4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
- INSIDERDirector Vizirgianakis Stavros G. was granted 323,275 shares, increasing direct ownership by 4% to 7,838,845 units (SEC Form 4)4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
- INSIDERChief Operating Officer Schallenberger Mark A. was granted 450,000 shares and covered exercise/tax liability with 7,070 shares, increasing direct ownership by 67% to 1,106,087 units (SEC Form 4) (withholding obligation)4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
- INSIDERCFO and Assistant Secretary Neils Scott C was granted 400,000 shares and covered exercise/tax liability with 28,155 shares, increasing direct ownership by 44% to 1,215,226 units (SEC Form 4) (for withholding tax)4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
- INSIDERPresident and CEO Browne Sean E was granted 550,000 shares and covered exercise/tax liability with 10,605 shares, increasing direct ownership by 21% to 3,114,669 units (SEC Form 4) to satisfy withholding obligation4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
- SECSEC Form 10-Q filed by Xtant Medical Holdings Inc.10-Q - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- SECXtant Medical Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- PRXtant Medical Reports Second Quarter 2026 Financial ResultsLaunched Trivium™ Shaped, an extension of its Trivium line of premium, next-generation demineralized bone matrix allograft for bone grafting proceduresCompany to host investor conference call and webcast today, August 11th, at 8:30am ETBELGRADE, Mont., Aug. 11, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today reported financial and operating results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial HighlightsGenerated total revenue of $23.0 million for the second quarter of 2026, as
- SECXtant Medical Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- PRXtant Medical to Announce Second Quarter 2026 Financial Results on August 11, 2026BELGRADE, Mont., Aug. 6, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it will release its financial results for the second quarter ended June 30, 2026, before the start of trading on Tuesday, August 11, 2026. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call at 8:30 AM ET on that day. Conference Details:Conference Date: Tuesday, August 11, 2026Conference Time: 8:30 AM ETConference Dial-in: 888-506-0062International Di
- PRXtant Medical to Participate in the Canaccord Genuity 46th Annual Growth ConferenceBELGRADE, Mont., Aug. 4, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that Sean Browne, CEO, Scott Neils, CFO, and Mark Schallenberger, COO, will be participating in the Canaccord Genuity 46th Annual Growth Conference, which is being held August 11-13, 2026, in Boston. The company's presentation is scheduled for Tuesday, August 11th, at 2:00 pm ET. A live webcast of the presentation will be available here. A replay will be posted to the Presentation & Events page of Xtant's Investors website f
- SECSEC Form DEFA14A filed by Xtant Medical Holdings Inc.DEFA14A - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- SECSEC Form DEF 14A filed by Xtant Medical Holdings Inc.DEF 14A - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- SECSEC Form SD filed by Xtant Medical Holdings Inc.SD - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- SECSEC Form S-8 POS filed by Xtant Medical Holdings Inc.S-8 POS - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- SECSEC Form S-8 POS filed by Xtant Medical Holdings Inc.S-8 POS - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- SECSEC Form S-8 POS filed by Xtant Medical Holdings Inc.S-8 POS - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- SECSEC Form S-8 POS filed by Xtant Medical Holdings Inc.S-8 POS - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- SECSEC Form 10-Q filed by Xtant Medical Holdings Inc.10-Q - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- SECXtant Medical Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- PRXtant Medical Reports First Quarter 2026 Financial ResultsRaises full-year 2026 revenue guidance to a range of $101-$105 millionSignificantly strengthens balance sheetEnters into exclusive U.S. distribution agreement for Dilon Technologies' HEMOBLAST® Bellows product for high-performance hemostasis; hires Dilon's U.S. sales teamBELGRADE, Mont., May 13, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today reported financial and operating results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Hi
- PRXtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026BELGRADE, Mont., May 7, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it will release its financial results for the first quarter ended March 31, 2026, before the start of trading on Wednesday, May 13, 2026. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call at 8:30 AM ET on that day. Conference Details:Conference Date: Wednesday, May 13, 2026Conference Time: 8:30 AM ETC
XTNT FAQ
6 questionsWhat does Xtant Medical Holdings Inc. do?
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis...Where does XTNT stock trade?
Xtant Medical Holdings Inc. (XTNT) is listed on AMEX.What sector and industry is XTNT in?
Xtant Medical Holdings Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about XTNT?
Xtant Medical Holdings Inc. has had 1 recent analyst action on file. The most recent action was from BTIG Research: Buy with a $200.00 price target on 2023-12-05. Recent price targets cluster around $200.00.What companies are similar to XTNT?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare XTNT side-by-side with any of them on Quantisnow.How can I track XTNT on Quantisnow?
Quantisnow aggregates Xtant Medical Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow XTNT to receive live email and push alerts on every new disclosure.